

rebioin journal
OF BIOSCIENCES

CAR-T Therapy in Precision Immuno-Oncology: Advancing Cancer Treatment through Chimeric Antigen Receptor Technology

admin@reboin.com www.rebioin.com

"CAR-T Therapy in Precision Immuno-Oncology: Advancing Cancer Treatment through Chimeric Antigen Receptor Technology"

Anchal Dubey[1], Akshita Panthi[2], and Shashwat[3]

[1,2]School of Bio-Science and Engineering and Artificial Intelligence (SBET), VIT Bhopal University

[3]Bhopal-Indore Highway, Kothrikalan, Sehore, Madhya Pradesh, India

Abstract

This review places the pioneering CAR-T (Chimeric Antigen Receptor T Cell) therapy in the context of cancer immunotherapy. CAR-T therapy leverages the patient's immune response by using genetically modified T cells to recognize and destroy cancer cells. The methodology defines the stringent process of manufacturing CAR-T cells through leukapheresis, gene modification, and subsequent infusion. Through its focus on precision, CAR-T therapy is impactful in hematologic malignancies and considers its prospects in solid tumors. This review highlights the role of CAR-T therapy in overcoming resistance, minimizing collateral damage, and adapting to individual genetic profiles. The Fundament way of action involves targeted recognition and destruction of cancer cells, focusing on the CD19 receptor in B-cell neoplasms. Challenges and advances, such as immune reactions and next-generation CAR-T approaches, are also presented. The ongoing research into multi-antigen targeting and universal CAR-T cells reflects the dynamic nature of this promising cancer therapeutic modality. In general, CART therapy is an individualized and potent treatment modality in immunotherapy with the potential to improve cancer treatment outcomes.

I. INTRODUCTION

Immunotherapy, particularly exemplified by CAR-T cell therapy, has surfaced as an innovative strategy in the pursuit of precision cancer treatment. This approach utilizes the immune system of the body to target cancer, representing a crucial advancement in personalized and targeted therapeutic interventions [1]. To establish a foundational understanding, it is necessary to clarify that immunotherapy constitutes a biological treatment modality that employs immune system mechanisms to address diseases, including cancer, while precision medicine customizes treatment strategies according to individual genetic characteristics [2].

CAR-T cell therapy, denoting chimeric antigen receptor Tcell therapy, represents a sophisticated intervention for aggressive malignancies [3]. This methodology improves the ability of T cells to identify and destroy cancer cells. The procedure includes the extraction of T cells from patients, genetic modification to express chimeric antigen receptors (CARs) that target specific cancer antigens, in vitro expansion, and subsequent reinfusion into patients [4]. Before CAR-T cell administration, patients typically undergo preparatory lowdose chemotherapy to increase effectiveness and reduce the risk of immune rejection [5].

Despite its therapeutic promise, CAR-T therapy presents certain potential complications, including neurological sequelae [6] and hypogammaglobulinemia [7], which require meticulous clinical oversight. However, developments such as nextgeneration CAR-T therapies [8] and integrative approaches with immune checkpoint inhibitors [9] continue to optimize safety profiles and therapeutic efficacy. This pioneering treatment modality constitutes a significant advancement in cancer management.

A. Role of CAR-T Therapy

The efficacy of CAR-T therapy has been thoroughly demonstrated to recognize various malignancies, including leukemia, breast cancer, and other hematologic cancers [1]. These aggressive cancers frequently escape immune surveillance, resulting in uncontrolled tumor proliferation and metastasis. CAR-T therapy stands as one of the most

potent immunotherapeutic approaches due to its utilization of genetically engineered autologous T cells, which demonstrate enhanced specificity compared to conventional T cells [2]. Through modification of cells with chimeric antigen receptors, CAR-T therapy facilitates the specific targeting of neoplastic cells and their altered surface markers, a vital component in stopping further tumor progression [3].

Precision Targeting for Minimal Damage CAR-T therapy exemplifies precision medicine through its selective identification and eradication of cancer cells while limiting collateral effects on healthy tissues [4]. This focused strategy is fundamental to maximize therapeutic effectiveness while minimizing the adverse reactions associated with conventional interventions [5].

Conquering Resistance in Cancer Treatment As highlighted in the contemporary literature, a significant advantage of CAR-T therapy lies in its ability to overcome resistance commonly encountered in traditional cancer treatments. This innovation presents considerable potential to improve patient outcomes and address therapeutic failures observed with chemotherapy and other conventional modalities [6].

Personalized Treatment Tied to Genetic Profiles CART therapy represents the vanguard of personalized medicine, tailoring treatment according to individual tumors' genetic and molecular signatures. This methodology improves therapeutic efficacy by accounting for the distinct biological characteristics of each malignancy, thus optimizing patient outcomes [7].

Success in Hematologic Malignancies The transformative achievements of CAR-T therapy in the management of hematologic cancers illustrate its therapeutic potential. Its clinical effectiveness validates its continued application and establishes it as a viable alternative for patients who require sophisticated and effective treatment strategies [8].

Continuous ongoing research for CAR-T therapy is expanding the application of CAR-T therapy from hematologic malignancies to solid tumors. This new frontier in cancer research represents a crucial step toward broadening the potential of CAR-T therapy and improving treatment outcomes in a wider range of cancers [9].

The generation of CAR-T cells involves a series of meticulously controlled steps, with continuous quality control assessments throughout the process [10]. The procedure begins with blood collection via leukapheresis(removal of WBC from the blood, separating them from other blood components such as RBCs, plasma, and platelets). In some cases, an additional step is performed to separate T-cell subsets according to the CD4/CD8 ratio using antibody-conjugated beads or specific markers [8]. Once leukocytes are enriched with T cells, the activation process begins. Rather than relying solely on antigenpresenting cells (APCs), researchers utilize antibody-coated magnetic beads to efficiently activate T cells, as these beads can be removed later [7]. Active T cells are then expanded using perfusion bioreactors such as the WAVE bioreactor, with the addition of interleukin-2 (IL-2) to stimulate rapid proliferation [6].

A crucial step in optimizing the functionality of CAR-T cells involves modifying the phenotype of T-cells, particularly shifting from Th2 or Th17 profiles to enhance their effectiveness [5]. Next, chimeric antigen receptors (CARs) are introduced into T cells using viral vectors, such as lentiviral vectors, to ensure stable integration of the introduced RNA into the cellular DNA [4]. This genetic modification results in the formation of CAR-T cells, which are subsequently cultured to expand the population to the required therapeutic levels [3]. Cell growth and expansion are conducted in specialized environments like the G-Rex system or WAVE bioreactors. Furthermore, an advanced system, CliniMACS, can streamline multiple steps in a single setup [2]. Once cell cultures reach the necessary confluence (typically exceeding 70-80 percent), the CAR-T cells are cryopreserved for future use and ultimately infused back into the patient, marking the completion of the CAR-T cell generation process in a simplified manner [1].

A. Mechanism

As discussed in the review, CAR-T cells function by recognizing specific antigenic cell surface markers and eliminating tumor cells [5]. A key example of this mechanism is the interaction between CAR-T cells and the CD19 receptor on malignant B-cells. The CD19 receptor is a transmembrane glycoprotein that plays a crucial role in B-cell development and function [4].

CAR-T cells are customized to recognize the CD19 receptor more specifically, which allows them to target malignant Bcells that express this marker selectively [3]. This precision targeting capability improves the efficacy of treatment by minimizing damage to healthy cells while effectively eliminating cancerous ones [2]. The specificity of CD19 receptor as a therapeutic target underscores its potential to advance immunotherapeutic strategies for B-cell malignancies [1].

Fig. 1: Schematic representation of CAR-T cell structure and mechanism of action. (a) The chimeric antigen receptor (CAR) is composed of an extracellular antigen-recognition domain derived from antibody variable regions, a hinge



and transmembrane region, one or more co-stimulatory domains, and a T-cell activation domain. (b) CAR genes are introduced into T cells via viral vectors, leading to the expression of CAR proteins on the T-cell surface. These engineered T cells specifically recognize and bind to CD19 antigens on the surface of cancer cells, enabling targeted immune attack.

B. CD19 Receptor of B-Cell

CD19 stands for Cluster of Differentiation 19 is a transmembrane glycoprotein come from immunoglobulin superfamily, it weighs around 95 kDa. It is expressed primarily in B cells throughout their development, from early progenitors to mature B lymphocytes [9]. CD19 plays a key role in B-cell receptor (BCR) signaling by acting as a co-receptor alongside CD21 and CD81, facilitating B-cell activation [8]. CD19 is a key therapeutic target in CAR-T therapy due to its high expression on malignant B cells, including those found in B-cell acute lymphoblastic leukemia (B-ALL) and certain lymphomas [7]. The chimeric antigen receptor (CAR) recognizes the extracellular domain of CD19, triggering a cytotoxic immune response [6]. Structurally, CAR consists of an extracellular single chain variable fragment (scFv) for antigen targeting, the transmembrane domain, and an intracellular domain incorporating key T-cell receptor (TCR) signaling elements, such as CD3(zeta) and co-stimulatory domains (CD28, 4-1BB) [5].

Upon binding to CD19, CAR-T cells induce apoptosis in malignant cells by releasing perforin and granzymes [4]. However, a significant limitation of CAR-T therapy is tumor antigen loss, where cancer cells downregulate CD19 expression to avoid treatment [3]. To address this, ongoing research focuses on bi-specific CARs targeting multiple antigens and dual CAR-T cell strategies to improve therapeutic efficacy [2]. Another challenge is cytokine release syndrome (CRS), a frequent side effect of excessive immune activation. This can be managed using anti-cytokine therapies, such as tocilizumab, an IL-6 receptor antagonist, to mitigate severe inflammatory responses [1].



Fig. 2: Structure and signaling of the CD19 molecule and its role in the B cell co-receptor complex. (Left) CD19 is a transmembrane protein composed of extracellular Ig-like C2 domains, a transmembrane region (TM), and a cytoplasmic tail containing tyrosine residues (Y391, Y482, Y513) that recruit signaling molecules such as Vav, PLC, PI3K, and Lyn upon phosphorylation. (Right) CD19 functions as part of the B cell co-receptor complex with CD21 and CD81, enhancing BCR signaling upon antigen (Ag) recognition. CD21 binds complement fragments (C3d), facilitating antigen recognition and signal amplification. [28]

C. Recognition of CD19 receptor in B-cell:

In B-cell malignancies, including specific types of leukemia and lymphoma, chimeric antigen receptors (CARs) are commonly engineered to target CD19, a surface protein expressed on most B cells, including malignant B-cell populations [8]. T cells are genetically engineered to express CARs on their surface, allowing them to recognize and attack CD19-expressing cells [7] specifically. A typical CAR construct consists of three key components: an extracellular domain that binds to CD19, a transmembrane domain, and an intracellular signaling domain [6]. Once introduced into the patient, the extracellular domain enables CAR-T cells to specifically recognize and bind to CD19-expressing malignant B cells [5]. This interaction stimulates intracellular signaling and T-cell activation takes place [4]. This activation prompts the release of cytotoxic molecules, such as perforin and granzymes, which ultimately results in the targeted destruction of B cells [3]. The CAR-T cell manufacturing process involves in vitro expansion to ensure a sufficient number of modified T cells before reinfusion into the patient via adoptive transfer [2]. In addition, some CAR-T cells exhibit persistence within the patient's immune system, contributing to immunological memory and offering prolonged surveillance against CD19-expressing cancer cells, reducing the probability of relapse [1].

D. Immune Response to CAR-T Cells

The activation of CAR-T cells takes place upon binding to their target antigen, triggering intracellular signaling cascades that drive their functional response. This activation leads to the release of cytotoxic molecules, which facilitates the destruction of tumor cells [8]. CAR-T cells exert their cytotoxic function by synthesizing granules containing perforin and granzymes(a family of cytotoxic serine proteases released by cytotoxic T lymphocytes and natural killer (NK) cells). Perforin penetrates the membrane of maligant cells and forms pores in the target cell membrane, allowing granzymes to enter and trigger apoptotic pathways, ultimately leading to tumor cell death [7]. Immune checkpoint molecules, such as programmed death-1 (PD-1) and cytotoxic T-lymphocyteassociated protein 4 (CTLA-4), regulate immune activation by modulating T-cell responses. CAR-T cells can express these immune checkpoint receptors, and their interaction with corresponding ligands on target cells or within the tumor microenvironment can influence therapy outcomes by enhancing or suppressing the immune response [6]. One of the key immune-mediated effects of CAR-T therapy is Cytokine Release Syndrome (CRS), a systemic inflammatory condition triggered by excessive cytokine secretion after CAR-T cell activation [5]. CRS is characterized by elevated levels of proinflammatory cytokines, including interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-α), and interferon-gamma (IFNγ), leading to symptoms ranging from mild fever to severe multi-organ dysfunction [4]. Beyond direct tumor cell killing, CAR-T cells interact with other immune cells within the tumor microenvironment, such as macrophages and natural killer (NK) cells, which can enhance or modulate the anti-tumor response [3]. In addition, some CAR-T cells persist in the patient's immune system, providing long-term immunological memory that contributes to sustained tumor surveillance and reduces the risk of relapse [2]. Even after its revolutionary success, CAR-T therapy has various challenges, such as the risk of immunogenicity, where the host's immune system recognizes and triggers a response against infused CAR-T cells, which affects its efficacy over time [1]. Research is ongoing to develop strategies that enhance the persistence of CAR-T cells while minimizing adverse immune-related effects.

III. NEXT GENERATION IN CAR-T CELLS

Overcoming Antigen Escape: CD19 and Beyond Antigen loss, particularly the downregulation or absence of CD19, remains a significant cause of relapse after CAR-T therapy. Studies have shown that sequential CAR-T therapies targeting alternative antigens, such as CD22, can induce clinical responses in patients with CD19 negative malignancies [9]. However, these approaches face similar challenges, as tumor cells may reduce CD22 expression, avoiding subsequent therapy [8]. These findings have catalyzed the evolution of next-generation CAR-T constructs designed to counteract such resistance mechanisms [19]. 2. Universal 'Off-the-Shelf' CAR-T Cells Researchers have developed allogeneic CART cells derived from healthy donors to enhance scalability and reduce manufacturing timelines. These "universal" CART cells undergo gene editing to eliminate endogenous Tcell receptors and major histocompatibility complex (MHC) markers, thus preventing graft-versus-host disease (GvHD) and immune rejection [25]. The CRISPR–Cas9 technology has allowed precise genome editing to mitigate the risks of GvHD by disrupting key genes involved in immune recognition [9]. However, this approach requires careful monitoring for off-target effects and long-term safety [3]. 3. Multi-Antigen Targeting to Overcome Tumor Heterogeneity Next-generation CAR-T cells have been engineered to simultaneously target multiple tumor-associated antigens to address tumor antigen heterogeneity and resistance. Dual targeting and tandem CAR constructs improve the recognition of heterogeneous cancer cell populations and reduce the risk of immune escape [4]. These modifications are significant in solid tumors, where antigen expression is often dynamic and heterogeneous, which means that there is no continuous pattern of antigen expression [19]. 4. CAR-Macrophages: A New Frontier In addition to T cells, macrophages have emerged as potential carriers for CAR-based therapies. CAR-engineered macrophages (CARM) are designed to take advantage of the phagocytic and antigen presenting capabilities of macrophages to stimulate robust immune responses. Preclinical models have shown encouraging anti-tumor activity, and early phase clinical trials such as those targeting HER2-expressing tumors (NCT04660929) are currently underway [9]. However, challenges remain in achieving efficient gene delivery and expansion, as CAR-M cells do not proliferate upon antigen encounter like T cells. Novel viral vectors such as Ad535 are being explored to improve the efficiency of CAR-M cell production [9][5]. Modulation of the Tumor Microenvironment with STING agonists - The immunosuppressive nature of the tumor microenvironment (TME) limits CAR-T cell efficacy, particularly in solid tumors. Incorporating STING (stimulator of interferon genes), agonists offer a strategy to remodel the TME. STING activation induces innate and adaptive immune responses by promoting the expression of type I interferons and other inflammatory cytokines [25]. Experimental models have shown that combining STING agonists, such as DMXAA, with CAR-T cells improves their infiltration, persistence, and cytotoxicity.

In addition, CAR-T cells engineered to express the RNA based STING agonist RN7SL1 have improved function and reduced immunosuppressive cell recruitment, even in tumors with antigen loss [9].

A. Clinical Trial 1

Aim and Methods used: Clinical trials play a vital role in approving CAR-T cell therapy. CD19 chimeric antigen receptor (CAR) T-cells have been approved for the treatment of relapsed and refractory (R/R) B-cell malignancies [26]. Several studies have investigated autologous 4-1BB costimulatory domain-engineered CD19 CAR-T cells in R/R B-cell lymphoma [16], [17].

Results: Severe cytokine release syndrome (CRS) was observed in 28.6 percent (4/14) of patients after CD19 CAR-T cell infusion [15,16]. After a 3-month trial observation period, an overall response rate of 77 percent (6/14 patients) was reported [16]. In addition, a high tumor burden (grade 3-4) and myelosuppression were observed, which contributed to CRS after chemotherapy [15], [16].

The following is the data given about several trials of multiple health conditions. Please prefer only leukemia and lymphoma. [2]



Fig. 3: CAR T-cell action: (A) CAR T-cells recognition of targeted antigen. (B) Chimeric antigen receptor binding to tumor-antigen. (C) Initiation of the antitumor (cytolytic) effects where the activated T-cells downstream the killing signaling by secreting granzymes and perforins, pro-inflammatory cytokines due to immune cell invasion, as well as initiating the expression of TRAIL and FasL pathways. [29]

The combination of CD19 CAR-T cells with PD-1 blockade improves antitumor efficacy, while CD19 CAR-T cells alone show limited ability to reduce intracranial tumor burden in patients with lymphoma [10,18,22]. CD19 CAR-T cells can induce tumor remission, and PD-1 inhibition can improve outcomes in relapsed / refractory (R/R) B-cell lymphoma, suggesting synergistic potential to overcome immune evasion mechanisms [10], [18], [22].

B. Clinical Trial 2

Aim, Purpose, and Methods Used: This phase I/IIa trial focuses on the efficacy and safety of CD19-targeted CART cell therapy in 15 patients with relapsed/refractory (R/R) B-cell lymphoma and leukemia [16], [17]. Patients received chemotherapy conditioning (low-dose cyclophosphamide and Fig. 4: The number of clinical trials. Several clinical trials have been investigating various malignancies as recorded by ClinicalTrials.gov. Based on the data up to January



lable toxicity, supporting their use after low-dose cyclophosphamide/fludarabine conditioning [14,16,17]. Biomarker profiling (e.g., IL-12, TRAIL, MDSCs) pre /post treatment can predict outcomes [1,15]. Combinatorial strategies, such as PD-1 blockade or gemcitabine to suppress MDSCs, could enhance long-term efficacy [10], [22].



2022, the number of these clinical trials is rising. The figure shows the number of CAR T-cell therapy clinical trials for hematological malignancies, solid tumors, and HIV infection (total = 789). (A) Hodgkin's lymphoma = 15 studies. (B) Acute myeloid leukemia = 35 studies. (C) Chronic lymphocytic leukemia = 74 studies. (D) Multiple myeloma = 114 studies. (E) NonHodgkin's lymphoma = 153 studies. (F) Acute lymphoblastic leukemia = 157 studies. (G) Human Immunodeficiency Virus = 6 studies. (H) Prostate Cancer = 10 studies. (I) Brain Cancer = 12 studies. (J) Renal Cancer = 12 studies. (K) Colorectal Cancer = 15 studies. (L) Ovarian Cancer = 16 studies. (M) Lung Cancer = 22 studies. (N)

Gastric Cancer = 19 studies. (O) Breast Cancer = 19 studies. (P) Pancreatic Cancer = 28 studies. (Q) Liver Cancer = 29 studies. (R) Malignant pleural mesothelioma = 4 studies. [29]

fludarabine) prior to CAR-T infusion [14], [24]. Blood samples were analyzed for CAR-T expansion, persistence, and immune responses using PCR, flow cytometry, and proteomic arrays [1], [16], [17].
Results: Safety: Third-generation CD19 CAR-T therapy demonstrated a manageable safety profile, with 4/15 patients hospitalized for cytokine release syndrome (CRS) or neurotoxicity [15], [16]. Efficacy: 6/15 patients achieved initial responses, including three lymphoma patients in remission at 3 months. 2 patients remained long-term progression-free [16], [17]. Biomarkers: Favorable immune profiles were correlated with high expression of IL-12, DC-LAMP, FasL, and TRAIL expression, along with reduced levels of IL-6, IL-8, NAP3, sPD-L1, and sPD-L2. Low monocytic myeloid-derived suppressor cells (MDSCs) were observed in the responders [1], [10], [15].
Third-generation CD19 CAR-T cells achieved a 40 percent response rate in advanced B-cell malignancies with controlFig. 5: Clinical course for all patients. DLBCLtr, diffuse large B cell lymphoma transformed from follicular lymphoma; FL-Burkitt, follicular lymphoma transformed to Burkitt lymphoma; MCL, mantle cell lymphoma; pre-B ALL, pre–B acute lymphoblastic leukemia; CLL, chronic lymphocytic leukemia; CR, complete remission; PR, partial remission; and PD, progressive disease. [30]

C. Improvement in CAR-T cell design

Chimeric antigen receptor T-cell therapy, or CAR-T therapy, has proven to be a promising method in cancer immunotherapy according to the most recent information. Technological developments are still shaping the effectiveness and architecture of CAR-T cells. Here are some improvements and developments in cutting-edge CAR-T cell design technologies.

Improved Methods of Targeting: Targeting cancer cells precisely is essential for reducing off-target effects. Research is still being done to improve the ability of CARs to identify and bind to particular tumor antigens, reducing the possibility of unwanted interactions of molecules. [1] This entails enhancing the design of single-chain variable fragments (scFv), investigating CARs that target two targets at the same time, and utilizing cutting-edge engineering methods to increase the specificity of cancer cell identification. [1]

Future-Generation CAR Architectures: Scientists are experimenting with a new CAR design that exceeds the standard single chain variable fragment (scFv) structure. [2] It consists of objects such as armored, split, and dual targeting CARs, each with special characteristics to increase safety and efficiency. These variations can achieve unique features such as improved cell signaling, improved tumor penetration, increased working in the tumor microenvironment, and advancing the capabilities of CAR-T cell therapy. [2]

Technologies for Gene Editing: CRISPR/Cas9 and other gene editing techniques improve CAR-T cells. This



involves Fig. 6: Overall survival of patients treated with CAR T cells (black line; n = 15). Patients with; lymphoma (gray broken line; n = 11); acute lymphoblastic leukemia (ALL; black dotted line; n = 4). The survival of lymphoma and ALL patients were not significantly different as evaluated by log-rank test. B, The patients were divided into those that did or did not respond to chemotherapy given during CAR T-cell manufacture (chemo response, black line; n = 7, and no response, dotted line; n = 8). The groups were significantly different as determined by log-rank test[30] improving the expression of the CAR construct, improving focus, and adding genetic changes to improve performance. [3]

Switching CAR-T Cells: To achieve greater precision in CAR-T cell activity, scientists are working to develop adjustable CAR-T cells. With this technology, physicians could have more flexibility in therapy management by activating or deactivating CAR-T cells as needed. [4]

By their ability to modify and control the treatment, switchable CAR-T cells present a curious new frontier in immunotherapy that may improve the efficacy and safety of CAR-T cell therapies. As research continues, further developments and improvements in switchable CAR-T cell technologies will probably come. [5]

CAR Immunogenicity - : The CAR construct by the host immune system may contribute to cytokine-related toxicities and therefore use human antibody fragments instead of murine-derived CARs to CAR Immunogenicity. [5] The ability of a CAR (chimeric antigen receptor) design to trigger an immunological response in the host organism is known as CAR immunogenicity. The safety and effectiveness of CART cell therapies may be impacted by this immunogenicity, which may also contribute to cytokine-related toxicities. Using human antibody fragments rather than murine-derived CARs in CAR design is one way to solve this problem. [6]

Brexucabtagene Autoleucel -: Brexucabtagene autoleucel, released by Gilead-Kite Pharma under the trademarked name Tecartus, was approved by the FDA on July 24, 2020, making it the third CAR T-cell therapy in the United States. Brexucabtagene autoleucel is a genetically engineered autologous T cell immunotherapy that drives CD19. It is the first and only approved CAR T-cell therapy for the treatment of adult patients with MCL (mantle cell lymphoma) that has progressed or is severe. Tecartus was designated an orphan drug and a breakthrough therapy. With a Priority Review, it was accepted under the Accelerated Approval Pathway. The approval was granted based on data from the main ZUMA-2 trial, which showed that 62 percent of participants experienced complete Remission (CR) following Tecartus treatment. [2]

D. Challenges

Challenges caused by Hypogammaglobulinemia from CAR-T cell therapy Infection is a significant risk caused by the Hypogammaglobulinemia factor in clinical trials. These risks can result in fungal infections, viral infections, and bacterial infections. Bacterial infections are most common among them. Hypogammaglobulinemia significantly increases susceptibility to bacterial, viral, and fungal infections, which are the most prevalent in clinical trials [12], [13]. This immunodeficiency arises from prolonged B-cell depletion, a direct consequence of CD19-targeted CAR-T therapy. Mechanistic Link: B-Cell Depletion and IgG Suppression B-cell aplasia—eliminating both malignant and healthy CD19+ B-cells—drives hypogammaglobulinemia by suppressing IgG production, impairing humoral immunity [?], [12], [13], [19]. This "on-target, off-tumor" effect is particularly detrimental in B-cell malignancies like chronic lymphocytic leukemia (CLL) and lymphoma, where immunoglobulin replacement therapy is often required to mitigate infection risks [12], [13].

Another significant challenging aspect that limits the outcomes of CAR-T cell therapy is Neurological Complications. Neurological complications involve and affect the parts of the nervous system- Peripheral Nervous System and Central Nervous System [27]. Neurological challenges in abundance can cause adverse effects on the patient's body as they increase health risk conditions. Two central syndromes releasing conditions arise after the therapy are- immune effector cell associated neurotoxicity syndrome (ICANS), previously known as cytokine release encephalopathy syndrome (CRES), which occurs in immune effector cells (IEC) and T lymphocytes used in treatments, causing the neuropsychiatric condition. Cytokine release syndrome (CRS) is another syndrome that can overlap the (ICANS). [3], [5] Neurological limitations in Chimeric Antigen Receptor T-cell therapy also adversely affect Immune Checkpoint Inhibitors [5]. Neurological complications affect the peripheral nervous system and central nervous system. If recognizable at an early stage so, it can be easily cured via effective steroid treatments. It can easily reduce the risk of short-term and long-term challenging complications. Therefore, early identification and treatment are required to minimize the future outcomes associated with ICPI and CAR T-cell immunotherapies. [6]

Effects on the Peripheral l Nervous System MG, Myositis, and Peripheral neuropathy are used in Chimeric Antigen Receptor (CAR) T-cell immunotherapy in the peripheral nervous system. [6], [11]

Immune checkpoint inhibitor (ICPI) therapy is connected by neuromuscular junction, linking to muscle-specific tyrosine kinase. Targeting both of them causes Myasthenia Gravis (MG)- an autoimmune disorder. Symptoms like ptosis and diplopia lead to more severe damage to the body, acquiring weakness, dyspnea, and dysphagia. Electromyography (EMG) can be used as a diagnostic tool for the acetylcholine receptor and muscle kinase-specific antibody regulation. [6]

Immune checkpoint inhibitor (ICPI) therapy and myositis association can overlap Myasthenia Gravis (MG) and acute inflammatory demyelinating polyneuropathy (AIDP) like conditions. Myositis is the crucial adverse event in neuro-muscular junctions, causing muscle pain and gradual proximal limb weakening. [7]

ICPI therapy also correlates to immune-mediated peripheral neuropathy, AIDP, and chronic inflammatory demyelinating polyneuropathy (CIDP) are also included in them. It affects the motor, sensory, and autonomic nervous systems [8]. They impacted cranial nerves, including facial, vestibulocochlear, and optic nerves. Sensory and motor impairments can cause Guillain-Barre syndrome (GBS). CIDP shuts down steroid response and associates high cerebrospinal fluid (CSF) protein levels. [9]

Effects on the Central Nervous System Hypophysitis, Aseptic meningitis, and Encephalitis are used in Chimeric Antigen Receptor (CAR) T-cell immunotherapy in the central nervous system. [6]

Using CTLA-4 can result in pituitary infiltration and pituitary cells' expression, leading to antibody formation and complement deposition. It includes headaches, neck pain, visual abnormalities, vertigo, and weakness. [7], [9]

Aseptic meningitis creates impact of symptoms like fever, headaches, and neck stiffness. Confusion, aphasia, agitation, altered mental status, and psychiatric symptoms are shown in Encephalitis. [8]

IV. CONCLUSION AND FUTURE WORK

In the 21st century, we've seen many amazing things, but one big problem is cancer. Scientists are working hard to find ways to help people with cancer, and one exciting treatment is called immunotherapy. It's like using our body's defenses to fight against the sickness. In the world of immunotherapy, CAR-T therapy is a special kind of therapy. It's like a small but powerful part of the whole picture. CAR-T cell therapy plays a vital role in treating patients suffering

from blood cancers like leukemia and lymphoma by targeting neoplastic cells treated with the patient's T-cells. They also increase the cellular cytotoxicity and induction of Tcell; there are many side effects behind this therapy, which later can cause lifethreatening challenges and risks to the body, causing adverse effects of infections. These infection risks are attributed to several factors, such as cytokine release, B-cell aplasia, neurological risk factors, and hypogammaglobulinemia. It changes our T-cells by giving them some genetic material from the harmful thing we want to fight, like cancer. This makes these modified T-cells, called CAR-T cells, super effective in stopping the growth of tumors . Even though we're still testing CAR-T therapy in different trials to ensure it works well, it's already looking better than the older methods like chemotherapy and radiotherapy. What's cool about CAR-T is that it's personalized – it's made to match each person's immune system. As we keep learning more about cancer and how to treat it, CAR-T therapy seems like an excellent step forward. Even though there are still some things we're figuring out, many people believe CAR-T therapy is a big hope for treating cancer in a better way. In summary, CART therapy is a special kind of immunotherapy showing much promise in the fight against cancer. It's a new and better way to use our body's defenses to tackle this tough illness. We're on the right track, and with more research and teamwork, CART therapy could be a game-changer in treating cancer. [2][3][5][7]

Combining anti-PD-1 with anti-CD30 CAR-t therapy implies anti-tumor activity r/r CD30+ lymphomas. Also, this study supports the PD-1/PD-L1 axis in antiCD30 CAR-T cell therapies.

REFERENCES

[1] Levstek, L., et al. "Biomarkers for prediction of CAR T therapy outcomes: current and future perspectives." Frontiers in Immunology, 15 (2024): 1378944.

[2] Rath, S., et al. "CAR-T-cell therapy in meningioma: current investigations, advancements and insight into future directions." Annals of Medicine and Surgery, 86.10 (2024): 5957-5965.

[3] Ross, M., Breman, E. "Engineering strategies to safely drive CAR Tcells into the future." Frontiers in Immunology, 15 (2024): 1411393.

[4] Liu, Y., et al. "Advanced Strategies of CAR-T Cell Therapy in Solid Tumors and Hematological Malignancies." Recent Patents on AntiCancer Drug Discovery, 19(5) (2024): 557-572.

[5] Saleki, K., Mohamadi, M. H., Alijanizadeh, P., Rezaei, N. "Neurological adverse effects of chimeric antigen receptor T-cell therapy." Expert Review of Clinical Immunology, 19(11) (2023): 1361–1383. https://doi.org/10.1080/1744666X.2023.2248390.

[6] Khalid, F., et al. "Neurological adverse effects of immune checkpoint inhibitors and chimeric antigen receptor T-cell therapy." World Journal of Oncology, 14(2) (2023): 109-118. https://doi.org/10.14740/wjon1575.

[7] Mitra, A., et al. "From bench to bedside: the history and progress of CAR T cell therapy." Frontiers in Immunology, 14 (2023): 1188049.

[8] Sterner, R. M., Sterner, R. M. "CAR T cell therapy: current limitations and potential strategies." Nature Reviews Immunology, 23(11) (2023): 727–741. https://www.nature.com/articles/s41577-023-00910-5

[9] Young, R. M., Engel, N. W., Uslu, U., Wellhausen, N., June, C. H. "Next-generation CAR T-cell therapies." Cancer Discovery, 12(7) (2022): 1625–1633. https://doi.org/10.1158/2159-8290.CD-21-1683

[10] Sang, W., et al. "Anti-PD-1 therapy enhances the efficacy of CD30directed chimeric antigen receptor T cell therapy in patients with relapsed/refractory CD30+ lymphoma." Frontiers in Immunology, 13 (2022): 858021. https://doi.org/10.3389/fimmu.2022.858021

[11] Alnefaie, A., et al. "Chimeric antigen receptor T-cells: An overview of concepts, applications, limitations, and proposed solutions. "Frontiers in Bioengineering and Biotechnology, 10 (2022): 797440. https://doi.org/10.3389/fbioe.2022.797440

[12] Wat, J., Barmettler, S. "Hypogammaglobulinemia after chimeric antigen receptor (CAR) T-cell therapy: Characteristics, management, and future directions." The Journal of Allergy and Clinical Immunology: In Practice, 10(2) (2022): 460-466. https://doi.org/10.1016/j.jaip.2021.08.006

[13] Kampouri, E., Walti, C. S., Gauthier, J., Hill, J. A. "Managing hypogammaglobulinemia in patients treated with CAR-T-cell therapy: Key points for clinicians." Expert Review of Hematology, 15(4) (2022): 305–320. https://doi.org/10.1080/17474086.2022.2063833

[14] Milone, M. C., et al. "Engineering-enhanced CAR T cells for improved cancer therapy." Nature Cancer, 2(8) (2021): 780-793.

[15] Schubert, M. L., et al. “Side-effect management of chimeric antigen receptor (CAR) T-cell therapy.” Annals of Oncology, 32(1) (2021): 34–48. https://doi.org/10.1016/j.annonc.2020.10.478
[16] Enblad, G., et al. “A phase I/IIa trial using CD19-targeted thirdgeneration CAR T cells for lymphoma and leukemia.” Clinical Cancer Research, 24(24) (2020): 6185–6194. https://doi.org/10.1158/10780432.CCR-20-2219
[17] Chen, X., et al. “A Phase I clinical trial of chimeric antigen receptormodified T cells in patients with relapsed and refractory lymphoma.” Immunotherapy, 12(10) (2020): 681–696. https://doi.org/10.2217/imt2020-0022
[18] Song, W., Zhang, M. “Use of CAR-T cell therapy, PD1 blockade, and their combination for the treatment of hematological malignancies.” Clinical Immunology, 214 (2020). https://doi.org/10.1016/j.clim.2020.108382
[19] Rafiq, S., Yeku, O., Yilmaz, A., Brentjens, R. J. “Optimizing CAR Tcell therapy: challenges and future directions.” Nature Reviews Clinical Oncology, 17(3) (2020): 147–16
[20] Seimetz, D., Heller, K., Richter, J. “Approval of first CAR-Ts: Have we solved all hurdles for ATMPs?” Cell Medicine (2019). https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6343443/
[21] Summary Basis for Regulatory Action – KYMRIAH. U.S. Food and Drug Administration (2017, August 30). https://www.fda.gov/media/107962/download
[22] Chong, E. A., et al. “PD-1 blockade modulates chimeric antigen receptor (CAR)–modified T cells: Refueling the CAR.” Blood, 129(8) (2017): 1039–1041. https://doi.org/10.1182/blood-2016-09-738385
[23] Kassim, S. “Toward an integrated model of product characterization for CAR-T cell therapy drug development efforts.” Immuno-oncology Insights (2017).
[24] Levine, B. L., et al. “Global manufacturing of CAR T cell therapy.” Molecular Therapy - Methods and Clinical Development, 4 (2017): 92–101. https://doi.org/10.1016/j.omtm.2016.12.006
[25] Trehin, P. V., Munoz-Guamuro, G., and Weber, W. (2023). Dynamic˜ fine-tuning of CAR-T cell therapy. Molecular Therapy - Oncolytics. https://doi.org/10.1016/j.omto.2023.06.001
[26] Hradska, K., Hajek, R., Hajek, R., Jelinek, T., and Jelinek, T. (2021). Toxicity of Immune-Checkpoint Inhibitors in Hematological Malignancies. Frontiers in Pharmacology. https://doi.org/10.3389/fphar.2021.733890
[27] Parts of the nervous system concept map – mind map- Edraw mind. https://www.edrawmind.com/mind-maps/28437/ parts-of the-nervous-system-concept-map
[28] June, C. H., O’Connor, R. S., Kawalekar, O. U., Ghassemi, S., and Milone, M. C. (2018). CAR T cell immunotherapy for human cancer. Science, 359(6382), 1361-1365
[29] Alnefaie, A., Albogami, S., Asiri, Y., Ahmad, T., Alotaibi, S. S., AlSanea, M. M., and Althobaiti, H. (2022). Chimeric antigen receptor T-cells: an overview of concepts, applications, limitations, and proposed solutions. Frontiers in bioengineering and biotechnology, 10, 797440.
[30] https://www.conferencemanager.dk/kraeftdag2022/downloadzip?data=318065

rebioin journal
OF BIOSCIENCES

CAR-T Therapy in Precision Immuno-Oncology: Advancing Cancer Treatment through Chimeric Antigen Receptor Technology



Plot no 977, GMS Road, near Balliwala Flyover, opposite Cubic Plaza, Dehradun, Uttarakhand 248001

admin@reboin.com

www.rebioin.com